Document Detail

Treatment of uremic hyperphosphatemia--is there still a need for aluminum salts?
MedLine Citation:
PMID:  3071137     Owner:  NLM     Status:  MEDLINE    
Aluminum-containing phosphate binders have been widely employed in the past in the management of uremic hyperphosphatemia. However, an increasing number of reports on aluminum toxicity has stimulated efforts to replace this therapy by safer methods. The aim of the present review is to critically evaluate other treatment strategies. It appears that aluminum-containing phosphate binders should no longer be considered the treatment of choice for controlling uremic hyperphosphatemia. Calcium carbonate, calcium citrate, magnesium carbonate and a mixture of ketoanalogues and amino acids present important therapeutical alternatives which could replace aluminum-containing phosphate binders in the majority of patients. However, it is mandatory, as these therapies also carry some risks, that side effects are detected early.
K Schaefer; D von Herrath; C M Erley
Related Documents :
170347 - The effect of chenodeoxycholic acid feeding on bile acid kinetics and fecal neutral ste...
3044647 - Determination of cholic acid and chenodeoxycholic acid pool sizes and fractional turnov...
6365507 - Ursodeoxycholic acid: a review of its pharmacological properties and therapeutic efficacy.
19029197 - Effect of ursodeoxycholic acid on liver function in children after successful surgery f...
6941627 - Dicarboxylic aciduria during ketotic phases in various types of glycogen storage disease.
9772157 - Dietary excess of vitamin b-6 affects the concentrations of amino acids in the caudate ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  American journal of nephrology     Volume:  8     ISSN:  0250-8095     ISO Abbreviation:  Am. J. Nephrol.     Publication Date:  1988  
Date Detail:
Created Date:  1989-05-11     Completed Date:  1989-05-11     Revised Date:  2007-02-14    
Medline Journal Info:
Nlm Unique ID:  8109361     Medline TA:  Am J Nephrol     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  173-8     Citation Subset:  IM    
St. Joseph-Krankenhaus I, Medizinische Abteilung II, Berlin.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alum Compounds / adverse effects,  therapeutic use*
Aluminum / therapeutic use*
Phosphates / blood*
Uremia / drug therapy*
Reg. No./Substance:
0/Alum Compounds; 0/Phosphates; 7429-90-5/Aluminum

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Significance of cyanide in medicolegal investigations involving fires.
Next Document:  Membranoproliferative glomerulonephritis in a patient with primary Sjögren's syndrome. Report of a ...